Skip to main content
CSL Ltd. logo

CSL Ltd. — Investor Relations & Filings

Ticker · CSL ISIN · AU000000CSL8 LEI · 529900ECSECK5ZDQTE14 ASX Manufacturing
Open in API
Filings indexed 2,555 across all filing types
Latest filing 2009-06-08 Transaction in Own Shar…
Country AU Australia
Listing ASX CSL

About CSL Ltd.

https://www.csl.com/

CSL is a global biotechnology company that researches, develops, manufactures, and markets a diverse portfolio of medicines. The company operates through distinct business units. CSL Behring provides plasma-derived and recombinant biotherapies for patients with rare and serious diseases, including bleeding disorders, immunodeficiencies, and neurological disorders. CSL Seqirus is a leading provider of vaccines, with a focus on influenza prevention and public health. CSL Vifor specializes in therapies for iron deficiency and nephrology, addressing the full spectrum of kidney disease. Collectively, CSL delivers lifesaving and life-enhancing treatments to a global patient population.

Recent filings

Filing Released Lang Actions
Announcement of buy-back - Appendix 3C 3 pages ?Kb
Transaction in Own Shares Classification · 100% confidence The document is titled 'Appendix 3C Announcement of buy-back' and contains detailed information about a company's on-market buy-back of shares, including the type of buy-back, class of shares, voting rights, number of shares, broker details, and compliance statements. It is a formal announcement related to the company's share repurchase activity. The content matches the description of a 'Transaction in Own Shares' filing, which reports the company buying back its own shares. The document is not a full financial report or earnings release but a specific announcement about share buy-back activity.
2009-06-08 English
CSL Receives Order from U.S,. Government for H1N1 Vaccine 2 pages ?Kb
Regulatory Filings Classification · 95% confidence The document is a press release dated 29 May 2009 announcing that CSL Limited has received a USD180 million order from the U.S. Government to produce a novel influenza vaccine. It contains no financial statements, no detailed financial data, no regulatory certifications, or meeting materials. The content is focused on a contract announcement related to manufacturing and supply of vaccines, which is a business update rather than a financial report or regulatory filing. The document length is 2965 characters, which is relatively short and typical for a press release. There is no indication that this is an earnings release or capital/financing update, nor is it a report publication announcement or regulatory filing. The best fitting category is a general regulatory announcement or business update, which falls under Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2009-05-28 English
Confirms commitment to Talecris acquisition 3 pages ?Kb
M&A Activity Classification · 95% confidence The document is a press release dated 28 May 2009 from CSL Limited regarding the company's intention to contest the US Federal Trade Commission's opposition to its proposed acquisition of Talecris Biotherapeutics. The content focuses on the merger/acquisition deal, regulatory challenges, and company statements about the transaction's benefits and competitive landscape. There are no financial statements, detailed financial performance data, or management discussion of financial results. The document is an announcement related to a merger and acquisition activity, specifically addressing regulatory opposition and the company's response. Therefore, the most appropriate classification is 'M&A Activity' (TAR). The document length (5090 characters) and content confirm it is a detailed announcement rather than a brief notice or a report publication announcement.
2009-05-27 English
CSL meets with US Federal Trade Commissioners re Talecris 1
M&A Activity Classification · 95% confidence The document is a press release dated 25 May 2009 announcing a meeting between CSL Limited's Managing Director and the US Federal Trade Commission regarding the proposed acquisition of Talecris Biotherapeutics. It discusses the FTC's recommendation to initiate legal action to block the transaction and mentions an imminent vote by the Commissioners. The document is an announcement related to merger activity but does not contain detailed merger documents or filings such as proxy statements or tender offers. It is not a full merger filing (MA) but rather an update on the M&A process. Given the content and context, the document fits best under M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length is short and it is not a report publication or regulatory filing. Confidence is high due to clear references to merger discussions and FTC involvement.
2009-05-24 English
Appendix 3B 7 pages ?Kb
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 3B New issue announcement' and references ASX rules related to new securities issuance and quotation. It details the issuance of additional ordinary shares under a Performance Rights Plan, including number of shares, terms, and quotation application. The document is a formal announcement of new share issuance and application for quotation on the ASX, consistent with Appendix 3B filings used in Australian markets for capital changes. It does not contain financial statements or detailed financial performance data, nor is it a report or presentation. It is clearly an announcement related to capital structure changes, specifically new share issuance and quotation. Therefore, the appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and detail support a high confidence in this classification.
2009-05-07 English
Proposed Acquisition of Talecris 1 page ?Kb
M&A Activity Classification · 95% confidence The document is a short announcement regarding market speculation about a proposed acquisition of Talecris Biotherapeutics by CSL Limited. It mentions regulatory consideration by the U.S. Federal Trade Commission but does not contain detailed merger documents or financial data. The text is brief (1039 characters) and serves as an update on the status of a potential M&A transaction rather than a formal merger filing or detailed report. Therefore, it fits best under the category of M&A Activity (TAR), which covers announcements related to merger proposals or takeover bids.
2009-05-06 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.